A sense of déjà vu: the debate surrounding state biosimilar substitution laws
- Collection:
- Health Policy and Services Research
- Series Title(s):
- Insight on the issues (AARP Public Policy Institute)
- Author(s):
- Purvis, Leigh, author
- Contributor(s):
- AARP (Organization) Public Policy Institute (AARP (Organization))
- Publication:
- Washington, D.C. : AARP Public Policy Institute, September 2014
- Language(s):
- English
- Format:
- Text
- Subject(s):
- Biological Products -- economics Biological Products -- therapeutic use Biosimilar Pharmaceuticals -- economics Biosimilar Pharmaceuticals -- therapeutic use Drug Costs Drug Substitution Legislation, Drug Drugs, Generic -- economics Federal Government State Government Humans United States United States. Food and Drug Administration. United States.
- Genre(s):
- Technical Report
- Abstract:
- The Affordable Care Act created an approval pathway for less expensive generic versions of biologic drugs, known as biosimilars, or follow-on biologics. However, new state legislation that could greatly limit the savings from biosimilars has ignited a debate similar to the one that followed the passage of federal legislation that encouraged the development of traditional generic drugs.
- Copyright:
- Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY-NC-ND license. (More information)
- Extent:
- 1 online resource (1 PDF file (5 pages)).
- NLM Unique ID:
- 101656652 (See catalog record)
- Permanent Link:
- http://resource.nlm.nih.gov/101656652